Factor VIII (medication)

Octapharma shares new data at ISTH 2022 in its mission to meet the challenges faced by people with bleeding disorders

Retrieved on: 
Monday, July 4, 2022
Efficacy, Von Willebrand disease, Product, Critical care, Head, DDAVP, Patient, Atomic mass, III, VWF, Adult, International Society on Thrombosis and Haemostasis, Factor VIII, Pharmacokinetics, Spotlight, Female, Gold, VIII, Plasma, Thrombosis, Awareness, Woman, Risk, Bleeding, Pensioner, BST, Immunotherapy, Haemophilia, RNA, Fondaparinux, Quality of life, Coagulopathy, VWD, PTP, Congress, Epitope, International Society, ISTH, Dietary supplement, Vaccine, Pharmaceutical industry, Birth control, Bookkeeping, Factor VIII (medication), Octapharma, Symposia, Safety

The data will be featured in eleven poster presentations and two Supported Symposia during this major international meeting.

Key Points: 
  • The data will be featured in eleven poster presentations and two Supported Symposia during this major international meeting.
  • Octapharma is proud to be a Gold Supporter of the ISTH 2022 Congress.
  • Safety and pharmacokinetics of a subcutaneous recombinant FVIII (OCTA101) in adult patients with severe haemophilia A. Presenting Author: Sigurd Knaub
    PB0559.
  • "Despite advances in the field, managing emergency bleeding and bleeding disorders still comes with considerable challenges.

Octapharma shares new data at ISTH 2022 in its mission to meet the challenges faced by people with bleeding disorders

Retrieved on: 
Monday, July 4, 2022
Efficacy, Von Willebrand disease, Product, Critical care, Head, DDAVP, Patient, Atomic mass, III, VWF, Adult, International Society on Thrombosis and Haemostasis, Factor VIII, Pharmacokinetics, Spotlight, Female, Gold, VIII, Plasma, Thrombosis, Awareness, Woman, Risk, Bleeding, Pensioner, BST, Immunotherapy, Haemophilia, RNA, Fondaparinux, Quality of life, Coagulopathy, VWD, PTP, Congress, Epitope, International Society, ISTH, Dietary supplement, Vaccine, Pharmaceutical industry, Birth control, Bookkeeping, Factor VIII (medication), Octapharma, Symposia, Safety

The data will be featured in eleven poster presentations and two Supported Symposia during this major international meeting.

Key Points: 
  • The data will be featured in eleven poster presentations and two Supported Symposia during this major international meeting.
  • Octapharma is proud to be a Gold Supporter of the ISTH 2022 Congress.
  • Safety and pharmacokinetics of a subcutaneous recombinant FVIII (OCTA101) in adult patients with severe haemophilia A. Presenting Author: Sigurd Knaub
    PB0559.
  • "Despite advances in the field, managing emergency bleeding and bleeding disorders still comes with considerable challenges.

Emergent BioSolutions Provides Corporate Governance Update

Retrieved on: 
Wednesday, March 23, 2022
Botulinum toxin, Private Securities Litigation Reform Act, Amherst College, NYSE, Technology assessment, Vaccine, Biotechnology, SEC, Emergent BioSolutions, Knowledge, Twitter, Â, GLOBE, Solution, Genetics, UCLA, Certified Public Accountant, Accounting, President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, Sale, Risk, Anderson School, York Region District School Board, Technology, Life, Therapy, Shareholder, Genentech, Growth, Calloway School of Business and Accountancy, Public health, EF Hutton, CDMO, College of Arts and Sciences, Instagram, LinkedIn, Factor VIII (medication), Leadership, Weill Cornell Medicine, Research, Albert Einstein College of Medicine, Emergent, United, EBS, Biomedicine, Johnson & Johnson, Management, Pharmaceutical industry, Indiana University, VideoRay UROVs, Medicine, Bayer, Microbiology

Zsolt Harsanyi, Ph.D., an independent director at Emergent since 2004, has been appointed as chairman of the board.

Key Points: 
  • Zsolt Harsanyi, Ph.D., an independent director at Emergent since 2004, has been appointed as chairman of the board.
  • He will serve as a member of the boards nominating and corporate governance and strategic operations committees.
  • Ronald B. Richard, lead independent director at Emergent, stated, We are pleased to welcome Keith Katkin to the board.
  • Dr. Zsolt Harsanyi has served as a director of Emergent BioSolutions since August 2004.